Moreover, an autophagy-inducing peptide totally suppressed the growth of ErbB2-positive xenografts30, implying that targeting ErbB2-mediated autophagy suppression might represent an attractive approach for ErbB2-positive breast cancer therapy. Here, ERBB2 is linked to breast carcinoma.